The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease.
Ellen BurgessFlorian M M BaeresGeorge BakrisHeidrun Bosch-TrabergMette GislumStephen C L GoughThomas IdornJack LawsonKenneth W MahaffeyJohannes F E MannHenriette MersebachVlado PerkovicKatherine TuttleRichard PratleyPublished in: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2023)
FLOW will evaluate the effect of semaglutide on kidney outcomes in participants with CKD and T2D, and is expected to complete in late 2024.